Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Takeda has agreed to sell a portfolio of OTC and prescription products in Latin America to Brazil's Hypera Pharma for 825 million dollars in cash. The deal is…
Japan's Takeda Pharmaceutical said on Monday it would sell some Latin American assets to Brazil's Hypera Pharma for 825 million dollars in cash, the latest in…
Fierce Pharma reported that Takeda netted roughly $940M from a pair of completed transactions, including the sale of its Latin American branded products to…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Takeda agreed to divest a portfolio of select OTC and prescription products in Latin America (Brazil, Mexico, Argentina, Colombia, Ecuador, Panama, Peru) to Brazilian pharma Hypera for $825M, part of Takeda's $10B non-core asset divestiture plan post-Shire acquisition. Transaction closed in 2021.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Hypera S.A. / Takeda Pharmaceutical Company Ltd. (this deal) | 2020 | $825M | — |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
| Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. | 2016 | $17.6B | 91 |
| DPx Holdings B.V. (JLL Partners 51% / Royal DSM 49%) / Patheon Inc. + DSM Pharmaceutical Products | 2013 | $2.6B | 90 |
| Pamplona Capital Management, LLP / PAREXEL International Corporation | 2017 | $5.0B | 90 |
← Browse all deals · How we score deals
More: 2020 deals · Other deals